



BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel OCT2022 Cycle 42 NExT SEP Committee Meeting

Date: December 7, 2022

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio

Place: National Institutes of Health

9000 Rockville Pike

Building 31, Room 3A44

Bethesda, Maryland 20892

(WebEx Meeting)

Contact Persons: Barbara Mroczkowski, Ph.D.

Executive Secretary

Discovery Experimental Therapeutics Program

National Cancer Institute, NIH

31 Center Drive, Room 3A44

Bethesda, Maryland 20817

301-496-4291

mroczkoskib@mail.nih.gov

Toby Hecht, Ph.D.

Executive Secretary

Development Experimental Therapeutics Program

National Cancer Institute, NIH

9609 Medical Center Drive, Room 3W110

Rockville, Maryland 20850

240-276-5683

toby.hecht2@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: November 7, 2022.

Melanie J. Pantoja,

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2022-24641 Filed: 11/10/2022 8:45 am; Publication Date: 11/14/2022]